BOSTON, Feb. 25, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies ...
KB407’s positive set of results presented at ATS 2026 follows a set of similar positive results that were announced for the ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly ...
The cystic fibrosis transmembrane conductance regulator (CFTR) is a complex protein that helps maintain fluid balance in several organs. Mutations in the CFTR protein can lead to symptoms of cystic ...
An experimental drug suggests that a 'path is clearly achievable' to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations. This includes about 11 percent of cystic ...
The drug is a small molecule with a novel mechanism of action, say David Bedwell, Ph.D., and Steven Rowe, M.D., MSPH, co-senior authors. Bedwell is professor and chair of the University of Alabama at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results